Clinical TrialJul 21, 2026, 05:02 PM
Telix Publishes Positive ProstACT SELECT Study Results for TLX591-Tx
AI Summary
Telix Pharmaceuticals announced the peer-reviewed publication of positive results from its ProstACT SELECT study in Cancers journal. The study confirmed the utility of 68Ga-PSMA-PET imaging for selecting patients for TLX591-Tx therapy, Telix's lead PSMA-targeting rADC therapy candidate. The publication highlighted TLX591-Tx's differentiated clinical profile, including an intensified dosing schedule, prolonged tumor retention, and a manageable safety profile, with a median radiographic progression-free survival of 8.8 months. These results support the ongoing ProstACT Global Phase 3 study for advanced metastatic prostate cancer.
Key Highlights
- ProstACT SELECT study results for TLX591-Tx published in peer-reviewed journal Cancers.
- Results confirm utility of 68Ga-PSMA-PET imaging for patient selection in TLX591-Tx therapy.
- TLX591-Tx demonstrated a median radiographic progression-free survival (rPFS) of 8.8 months.
- The therapy showed a manageable and predictable safety profile in a heterogeneous patient population.
- Highlights include intensified dosing, prolonged tumor retention, and low exocrine gland irradiation.
- TLX591-Tx is currently being evaluated in the ProstACT Global Phase 3 study for prostate cancer.
Price Impact
More from TLX